Key Takeaways:
Hong Kong pharmacy chain Lung Fung Group has passed its listing hearing to proceed with an initial public offering on the city's Main Board, with DBS acting as the sole sponsor.
According to its prospectus, which cites a Frost & Sullivan report, the company is a dominant player in the local market. In 2024, Lung Fung ranked as the largest pharmaceutical retailer in Hong Kong by retail sales value, capturing a 5.2% market share.
The IPO filing follows a period of strong financial performance. For the first eight months of its 2026 fiscal year ending in November, the company's revenue grew 34.7% year-over-year to HKD 2.035 billion. Profit for the same period surged 85.8% to HKD 148 million.
The company currently operates 31 stores across Hong Kong and intends to use the proceeds to fund an expansion, with plans to open 17 to 18 new retail locations over the next three years. Details such as the proposed ticker, offer price, and deal size were not yet disclosed.
The planned dividend policy, which aims to distribute no less than 50% of profits to shareholders, may appeal to investors. The success of the offering and its initial trading performance will serve as a key test of investor appetite for new listings in the Hong Kong market.
This article is for informational purposes only and does not constitute investment advice.
